The U.S. Food and Drug Administration (“FDA”) has opened the door for accelerated development and testing of investigational vaccines. While companies involved with these accelerated clinical trials may be concerned about exposing themselves to liability as a result, federal legislation is likely to offer broad protection. Companies should also consider taking additional steps to further buttress these legislative protections.
Click here for details.
Click here for our COVID-19 vaccines updates.